Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Tilly's (TLYS) Stock Dips On Dismal Holiday Sales & View Cut

Published 01/13/2020, 09:40 PM
Updated 07/09/2023, 06:31 AM
BBY
-
TGT
-
ZUMZ
-
TLYS
-

Shares of Tilly’s, Inc. (NYSE:TLYS) fell more than 22% during the trading session on Jan 13, after the retailer revealed sluggish holiday sales numbers and slashed view. Despite a robust Black Friday weekend and Cyber Monday, a sudden deceleration in sales and traffic in the second and third weeks of December weighed on the results of the holiday period.

Notably, comparable store sales declined 2% for the nine weeks, ended Jan 5, 2019, against growth of 5.8% in the prior-year period. The company witnessed dismal results in most of the geographical markets, except for New England, the Upper Midwest and Arizona. We note that the Southeast, Florida and Nevada regions were most affected in terms of comparable-store sales.

Further, comparable store sales in physical stores, which accounted for 80.5% of total sales in the nine weeks, slumped 2.7%. Meanwhile, e-commerce sales, which contributed 19.5% to total sales in the said period, inched up 1%. Moreover, comparable store sales for girls’ and women’s merchandises were positive but were more than offset by softness in other merchandising categories such as footwear and accessories.

Total sales for the nine weeks were $143.9 million, up 1.1% from $142.4 million reported in the prior-year period.

Owing to dismal results, management trimmed its fourth-quarter fiscal 2019 outlook. The company now anticipates a 2-3% decline in comparable store sales, whereas it earlier mentioned 2-5% growth. Adjusted earnings are expected to be 18-20 cents, down from 29-32 cents stated previously.

Nonetheless, the Zacks Rank #1 (Strong Buy) stock is leaving no stone unturned to get back on track. In this regard, store expansion plans, especially in the Northeast, comprising Texas and Chicago regions, along with improved loyalty program and investment in customer-facing technologies bode well. Such well chalked out efforts may provide some cushion to the stock, which has declined 7% in the past three months against the industry’s growth of 8.1%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Check Out These Other Solid Picks

Zumiez Inc (NASDAQ:ZUMZ) has a long-term earnings growth rate of 12%. It currently sports a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Best Buy (NYSE:BBY) presently has a long-term earnings growth rate of 8.7% and a Zacks Rank #2 (Buy).

Target Corp. (NYSE:TGT) currently has a long-term earnings growth rate of 7.6% and a Zacks Rank #2.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Zumiez Inc. (ZUMZ): Free Stock Analysis Report

Tilly's, Inc. (TLYS): Free Stock Analysis Report

Best Buy Co., Inc. (BBY): Free Stock Analysis Report

Target Corporation (TGT): Free Stock Analysis Report

Original post

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.